Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PD180970 + Serdemetan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PD180970 | PD 180970 | BCR-ABL Inhibitor 32 SRC Inhibitor 31 | PD180970 is an ATP-competitive tyrosine kinase inhibitor of Src and Abl, which can result in the inhibition of autophosphorylation and induce apoptosis (PMID: 10974196, PMID: 12499247, PMID: 27699828). | |
Serdemetan | JNJ-26854165|JNJ 26854165 | p53 Activator 11 | Serdemetan (JNJ-26854165) is a small molecule that regulates ABCA1 expression and inhibits cholesterol transport, resulting in activation of p53 and increased cell death in Tp53 wild-type and mutant cells (PMID: 23820125, PMID: 27999193). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|